scholarly journals Impact of Agaricus bisporus Mushroom Consumption on Gut Health Markers in Healthy Adults

Nutrients ◽  
2018 ◽  
Vol 10 (10) ◽  
pp. 1402 ◽  
Author(s):  
Julie Hess ◽  
Qi Wang ◽  
Trevor Gould ◽  
Joanne Slavin
Keyword(s):  
Agaricus Bisporus ◽  
Gastrointestinal Symptoms ◽  
Fecal Microbiota ◽  
Healthy Adults ◽  
Breath Hydrogen ◽  
Gut Health ◽  
Sample Collection ◽  
Stool Weight ◽  
Gastrointestinal Tolerance ◽  
Meat Diet

Eating Agaricus bisporus mushrooms may impact gut health, because they contain known prebiotics. This study assessed mushroom consumption compared to meat on gastrointestinal tolerance, short chain fatty acid (SCFA) production, laxation, and fecal microbiota. A randomized open-label crossover study was conducted in healthy adults (n = 32) consuming protein-matched amounts of mushrooms or meat twice daily for ten days. Breath hydrogen measures were taken on day one, and gastrointestinal tolerance was evaluated throughout treatments. Fecal sample collection was completed days 6–10, and samples were assessed for bacterial composition, SCFA concentrations, weight, pH, and consistency. There were no differences in breath hydrogen, stool frequency, consistency, fecal pH, or SCFA concentrations between the two diets. The mushroom diet led to greater overall gastrointestinal symptoms than the meat diet on days one and two. The mushroom-rich diet resulted in higher average stool weight (p = 0.002) and a different fecal microbiota composition compared to the meat diet, with greater abundance of Bacteroidetes (p = 0.0002) and lower abundance of Firmicutes (p = 0.0009). The increase in stool weight and presence of undigested mushrooms in stool suggests that mushroom consumption may impact laxation in healthy adults. Additional research is needed to interpret the health implications of fecal microbiota shifts with mushroom feeding.

scholarly journals Impact of Glucosamine Supplementation on Gut Health

Nutrients ◽  
2021 ◽  
Vol 13 (7) ◽  
pp. 2180
Author(s):  
Jessica M. Moon ◽  
Peter Finnegan ◽  
Richard A. Stecker ◽  
Hanna Lee ◽  
Kayla M. Ratliff ◽  
...  
Keyword(s):  
Gastrointestinal Symptoms ◽  
Short Chain Fatty Acids ◽  
Fecal Microbiota ◽  
Bowel Habit ◽  
Total Amino Acid ◽  
Crossover Fashion ◽  
Gut Health ◽  
Double Blind ◽  
Branched Chain ◽  
The Impact

Glucosamine (GLU) is a natural compound found in cartilage, and supplementation with glucosamine has been shown to improve joint heath and has been linked to reduced mortality rates. GLU is poorly absorbed and may exhibit functional properties in the gut. The purpose of this study was to examine the impact of glucosamine on gastrointestinal function as well as changes in fecal microbiota and metabolome. Healthy males (n = 6) and females (n = 5) (33.4 ± 7.7 years, 174.1 ± 12.0 cm, 76.5 ± 12.9 kg, 25.2 ± 3.1 kg/m2, n = 11) completed two supplementation protocols that each spanned three weeks separated by a washout period that lasted two weeks. In a randomized, double-blind, placebo-controlled, crossover fashion, participants ingested a daily dose of GLU hydrochloride (3000 mg GlucosaGreen®, TSI Group Ltd., USA) or maltodextrin placebo. Study participants completed bowel habit and gastrointestinal symptoms questionnaires in addition to providing a stool sample that was analyzed for fecal microbiota and metabolome at baseline and after the completion of each supplementation period. GLU significantly reduced stomach bloating and showed a trend towards reducing constipation and hard stools. Phylogenetic diversity (Faith’s PD) and proportions of Pseudomonadaceae, Peptococcaceae, and Bacillaceae were significantly reduced following GLU consumption. GLU supplementation significantly reduced individual, total branched-chain, and total amino acid excretion, with no glucosamine being detected in any of the fecal samples. GLU had no effect on fecal short-chain fatty acids levels. GLU supplementation provided functional gut health benefits and induced fecal microbiota and metabolome changes.

Gastrointestinal Tolerance to Daily Canned Chickpea Intake

2014 ◽  
Vol 75 (4) ◽  
pp. 218-221 ◽  
Author(s):  
Wendy J. Dahl ◽  
Abdulah Hanifi ◽  
Gordon A. Zello ◽  
Robert T. Tyler
Keyword(s):  
Abdominal Pain ◽  
Chronic Disease ◽  
Diet Quality ◽  
Gastrointestinal Symptoms ◽  
Crossover Design ◽  
Healthy Adults ◽  
Stool Frequency ◽  
Gastrointestinal Tolerance ◽  
Random Crossover

Purpose: Consumption of pulses is recommended to improve diet quality and decrease the risk of chronic disease. However, their constituent α-galactosides, including raffinose, are commonly thought to contribute to unpleasant gastrointestinal symptoms. Methods: Using a random crossover design, healthy adults (n = 12) received control foods, control foods with 5 g raffinose, and foods with 200 g of canned chickpea (11 g fibre per day), each for three weeks following a 3-day diet rotation. Gastrointestinal symptoms (rating 0 = none to 3 = severe), compliance, and stool frequency were recorded daily. Results: No change in daily stool frequency (mean ± SD) was found with chickpea (1.7 ± 0.3) or raffinose (1.7 ± 0.4) compared with control (1.5 ± 0.3). Reported flatulence (mean ± SD) was rated higher with chickpea (1.0 ± 0.2, P < 0.001) and raffinose (0.7 ± 0.2, P < 0.001) compared with control (0.4 ± 0.1). Although bloating was infrequent, ratings were higher with chickpea (0.2 ± 0.1, P < 0.001) and raffinose (0.3 ± 0.1, P < 0.001) compared with control (0.0). No differences were found for diarrhea or abdominal pain. Conclusions: As gastrointestinal symptoms were mild for most participants, canned chickpea may be a feasible way of increasing pulse intake and improving overall diet quality.

scholarly journals Gastrointestinal disturbance and effect of fecal microbiota transplantation in discharged COVID-19 patients

2021 ◽  
Vol 15 (1) ◽  
Author(s):  
Fengqiong Liu ◽  
Shanliang Ye ◽  
Xin Zhu ◽  
Xuesong He ◽  
Shengzhou Wang ◽  
...  
Keyword(s):  
B Cells ◽  
Fecal Microbiota Transplantation ◽  
Gastrointestinal Symptoms ◽  
Fecal Microbiota ◽  
Case Presentation ◽  
Microbiome Composition ◽  
Operational Taxonomic Units ◽  
Gut Dysbiosis ◽  
Rehabilitative Intervention ◽  
Oral Capsule

Abstract Background To investigate the potential beneficial effect of fecal microbiota transplantation (FMT) on gastrointestinal symptoms, gut dysbiosis and immune status in discharged COVID-19 patients. Case presentation A total of 11 COVID-19 patients were recruited in April, 2020, about one month on average after they were discharged from the hospital. All subjects received FMT for 4 consecutive days by oral capsule administrations with 10 capsules for each day. In total, 5 out of 11 patients reported to be suffered from gastrointestinal symptoms, which were improved after FMT. After FMT, alterations of B cells were observed, which was characterized as decreased naive B cell (P = 0.012) and increased memory B cells (P = 0.001) and non-switched B cells (P = 0.012).The microbial community richness indicated by operational taxonomic units number, observed species and Chao1 estimator was marginally increased after FMT. Gut microbiome composition of discharged COVID-19 patients differed from that of the general population at both phylum and genera level, which was characterized with a lower proportion of Firmicutes (41.0%) and Actinobacteria (4.0%), higher proportion of Bacteroidetes (42.9%) and Proteobacteria (9.2%). FMT can partially restore the gut dysbiosis by increasing the relative abundance of Actinobacteria (15.0%) and reducing Proteobacteria (2.8%) at the phylum level. At the genera level, Bifidobacterium and Faecalibacterium had significantly increased after FMT. Conclusions After FMT, altered peripheral lymphocyte subset, restored gut microbiota and alleviated gastrointestinal disorders were observe, suggesting that FMT may serve as a potential therapeutic and rehabilitative intervention for the COVID-19.

The role of gut dysbiosis in Parkinson's disease: mechanistic insights andtherapeutic options

Brain ◽  
2021 ◽  
Author(s):  
Qing Wang ◽  
Yuqi Luo ◽  
K Ray Chaudhuri ◽  
Richard Reynolds ◽  
Eng-King Tan ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Nervous System ◽  
Gut Microbiota ◽  
Fecal Microbiota Transplantation ◽  
Gastrointestinal Symptoms ◽  
Fecal Microbiota ◽  
Motor Symptoms ◽  
Treatment Paradigm ◽  
New Treatment

Abstract Parkinson's disease is a common neurodegenerative disease in which gastrointestinal symptoms may appear prior to motor symptoms. The gut microbiota of patients with Parkinson's disease shows unique changes, which may be used as early biomarkers of disease. Alteration in gut microbiota composition may be related to the cause or effect of motor or non-motor symptoms, but the specific pathogenic mechanisms are unclear. The gut microbiota and its metabolites have been suggested to be involved in the pathogenesis of Parkinson's disease by regulating neuroinflammation, barrier function and neurotransmitter activity. There is bidirectional communication between the enteric nervous system and the central nervous system, and the microbiota-gut-brain axis may provide a pathway for the transmission of α-synuclein. We highlight recent discoveries and alterations of the gut microbiota in Parkinson's disease, and highlight current mechanistic insights on the microbiota-gut-brain axis in disease pathophysiology. We discuss the interactions between production and transmission of α-synuclein and gut inflammation and neuroinflammation. In addition, we also draw attention to diet modification, use of probiotics and prebiotics and fecal microbiota transplantation as potential therapeutic approaches that may lead to a new treatment paradigm for Parkinson's disease.

Effects of Fructooligosaccharide Fortified Snack Foods on Gastrointestinal Symptoms in Healthy Adults

2012 ◽  
Vol 112 (9) ◽  
pp. A45
Author(s):  
A. Wright ◽  
B. Langkamp-Henken ◽  
A. Mathews ◽  
M. Christman ◽  
A. Radford ◽  
...  
Keyword(s):  
Gastrointestinal Symptoms ◽  
Healthy Adults ◽  
Snack Foods

Fecal microbiota analysis: an overview of sample collection methods and sequencing strategies

2015 ◽  
Vol 10 (9) ◽  
pp. 1485-1504 ◽  
Author(s):  
Vincent Thomas ◽  
James Clark ◽  
Joël Doré
Keyword(s):  
Fecal Microbiota ◽  
Sample Collection ◽  
Microbiota Analysis ◽  
Collection Methods

scholarly journals Assessing the Effects of Ginger Extract on Polyphenol Profiles and the Subsequent Impact on the Fecal Microbiota by Simulating Digestion and Fermentation In Vitro

Nutrients ◽  
2020 ◽  
Vol 12 (10) ◽  
pp. 3194
Author(s):  
Jing Wang ◽  
Yong Chen ◽  
Xiaosong Hu ◽  
Fengqin Feng ◽  
Luyun Cai ◽  
...  
Keyword(s):  
Gut Microbiota ◽  
Ph Value ◽  
Illumina Miseq ◽  
Short Chain Fatty Acids ◽  
Fecal Microbiota ◽  
Rrna Gene ◽  
Gut Health ◽  
Ginger Extract ◽  
Mixed Culture Fermentation

The beneficial effects of ginger polyphenols have been extensively reported. However, their metabolic characteristics and health effects on gut microbiota are poor understood. The purpose of this study was to investigate the digestion stability of ginger polyphenols and their prebiotic effects on gut microbiota by simulating digestion and fermentation in vitro. Following simulated digestion in vitro, 85% of the polyphenols were still detectable, and the main polyphenol constituents identified in ginger extract are 6-, 8-, and 10-gingerols and 6-shogaol in the digestive fluids. After batch fermentation, the changes in microbial populations were measured by 16S rRNA gene Illumina MiSeq sequencing. In mixed-culture fermentation with fecal inoculate, digested ginger extract (GE) significantly modulated the fecal microbiota structure and promoted the growth of some beneficial bacterial populations, such as Bifidobacterium and Enterococcus. Furthermore, incubation with GE could elevate the levels of short-chain fatty acids (SCFAs) accompanied by a decrease in the pH value. Additionally, the quantitative PCR results showed that 6-gingerol (6G), as the main polyphenol in GE, increased the abundance of Bifidobacterium significantly. Therefore, 6G is expected to be a potential prebiotic that improves human health by promoting gut health.

scholarly journals PSVIII-10 Effects of early intervention by fecal microbiota transplantation combined probiotics on the growth performance, intestinal barrier and immunity function, and gut microbiota in sucking piglets

2019 ◽  
Vol 97 (Supplement_3) ◽  
pp. 305-306
Author(s):  
Quanhang Xiang ◽  
Jian Peng
Keyword(s):  
Early Intervention ◽  
Growth Performance ◽  
Fecal Microbiota Transplantation ◽  
Intestinal Barrier ◽  
Short Chain Fatty Acids ◽  
Fecal Microbiota ◽  
Gut Health ◽  
Gut Colonization ◽  
Fecal Suspension ◽  
Immunity Function

Abstract The objective of this study was to investigate the effects of early gut colonization by fecal microbiota transplantation and probiotics intervention on growth performance, immunity function, and gut health of piglets. A total of 121 pregnant sows were divided into 6 groups with average parity of 3.66 ± 1.34. After delivery, piglets of group AB were treated with antibiotics at age of 3-day. Piglets of group CON were gavaged with PBS. The remaining four treatment groups, FMT, FMT+C, FMT+S, and FMT+C+S, the piglets were gavaged with fecal suspension, fecal suspension with C. butyricum, fecal suspension with S. boulardii, and fecal suspension with C. butyricum and S.boulardii, respectively, with the frequency of once daily in the first 3 days. All the piglets were weaned at age of 21 day. The individual body weight of piglets were weighed weekly, blood samples and fecal samples were collected weekly. At the end of study, the ADG and diarrhea rate were caculated. FMT+C+S and FMT could increased piglets 21-day-old weight (P &lt; 0.01), and FMT+C+S could increased ADG (P &lt; 0.05) and decreased diarrhea rate (P &lt; 0.05). Early antibiotics exposure for health care has no positive effect on growth performance and diarrhea. FMT, FMT+S and FMT+C+S improved fecal sIgA and plasma IgG of 14-day-old piglets (P &lt; 0.05). FMT+C+S decreased the concentration of plasma DAO and D-LA, and increased fecal MUC2 content, so that the intestinal barrier was enhanced. The early intervention of FMT combined with C. butyricum and S. boulardii reduced the abundance of E. coli, and increased the abundance of Lactobacillus, Bifidobacterium and Faecalibacterium prausnitzii. In addition, it also increases the production of intestinal short-chain fatty acids. In conclusion, these data indicated that early intervention with FMT combined C. butyricum and S. boulardii could improve the growth performance, immune responses, and gut function of sucking piglets.

Sign in / Sign up

Export Citation Format

Share Document